Chan Mitchell
Chief Financial Officer
Chan Mitchell has filed 5 SEC Form 4 filings (5 transaction rows) across 2 companies, including RGNX, AVTX, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Sep 3, 2026.
On the most recent filing, Chan Mitchell is listed as Director at Avalo Therapeutics, Inc. Inside the rolling window, Chan Mitchell reported no open-market purchases and 1 open-market sale totaling $72K in AVTX.
Companies traded
Other insiders at RGNX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$72K
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Chan Mitchell made?
Chan Mitchell has filed 5 SEC Form 4 filings (5 transaction rows) across 2 companies, including RGNX, AVTX since 2025.
Which companies does Chan Mitchell trade?
Chan Mitchell has filed SEC Form 4 disclosures for 2 companies, including RGNX, AVTX.
When was Chan Mitchell's most recent SEC Form 4 filing?
Chan Mitchell's most recent SEC Form 4 filing on Tracefour is dated Sep 3, 2026.
What is Chan Mitchell's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Chan Mitchell is listed as Chief Financial Officer.
What is Chan Mitchell's total buy and sell value in the current window?
Inside the rolling retention window, Chan Mitchell bought $0 and sold $72K based on SEC Form 4 filings.
What was Chan Mitchell's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 3,167 AVTX shares on 2026-05-06, worth $72K, per SEC Form 4 filings.